Overview

Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

NIPISAFE is open-label, phase II study, to identify a combination scheme of nivolumab and ipilimumab with a high level of clinical activity, but with a lower toxicity in MSI/dMMR Metastatic Colorectal Cancer (mCRC) patients.

Phase:

Phase 2

Details

Lead Sponsor:

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborator:

Bristol-Myers Squibb

Treatments:

Ipilimumab
Nivolumab